TXG

10x Genomics, Inc. [TXG] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

TXG Stock Summary

Top TXG Correlated Resources

TXG


Top 10 Correlated ETFs

TXG


Top 10 Correlated Stocks

TXG


In the News

10:46 26 Sep 2023 TXG

10x Genomics: Recent Performance Amplifies My Bullish Conviction

10x Genomics reported impressive Q2 performance with revenue growing by 28% YoY to reach $147M. The company's growth is driven by strong performance in both single-cell and spatial biology portfolios. Despite challenges in the Chinese market and a decrease in gross margin, 10x Genomics remains well-positioned for growth with a strong cash position.

11:16 26 Sep 2023 TXG

10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

08:16 26 Sep 2023 TXG

10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates

10x Genomics (TXG) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.57 per share a year ago.

11:56 26 Sep 2023 TXG

Goldman Sachs Maintains 10x Genomics Inc – (TXG) Sell Recommendation

Fintel reports that on July 13, 2023, Goldman Sachs maintained coverage of 10x Genomics Inc – (TXG) with a Sell recommendation.

10:55 26 Sep 2023 TXG

10x Genomics: Growth Outweighing The Risks

10x Genomics has been on my Compounding Healthcare “Bio Boom” speculative portfolio watch list since its IPO back in 2019. I believe 10x Genomics is becoming an entrenched name. After performing some analysis, I believe the company's growth record and prospects outweigh the risks at this point. I am moving it up on my watch list. The medicines of the future will rely upon the technology that 10x is involved in. Clearly, this could lead to a massive market opportunity for the company.

02:21 26 Sep 2023 TXG

Red-Hot Quality Opportunities in Genomics

The health care sector is currently undergoing a remarkable transformation. The recent focus on genomics has empowered medical professionals to diagnose patients more objectively and adopt proactive measures to maintain the well-being of larger populations.

10:24 26 Sep 2023 TXG

CEO Serge Saxonov Sells 2,602 Shares of 10x Genomics Inc (TXG)

On May 23, 2023, Serge Saxonov, CEO of 10x Genomics Inc ( TXG , Financial), sold 2,602 shares of the company's stock. This insider sell comes amidst a year of insider transactions that have seen Saxonov sell a total of 15,934 shares and make no purchases.

11:43 26 Sep 2023 TXG

How 10x Genomics Provides A View Into The Body's Cellular Warfare

It could be an inflection year for 10x Genomics, one analyst says. TXG stock bounded off a low in October and is now on a seven-month sprint.

04:05 26 Sep 2023 TXG

3 DNA Stocks to Buy for the Synthetic Biology Revolution

Biology is the study of life. And synthetic biology is the creation of new life for new purposes.

01:53 26 Sep 2023 TXG

A Deep Dive Into 10x Genomics, A Promising Portfolio

10x Genomics develops cutting-edge platforms for single-cell and spatial analysis, driving advances in disease research and drug discovery. Despite market fluctuations, their strong product pipeline is expected to fuel revenue growth and expand their customer base.

TXG Financial details

Company Rating
Buy
Market Cap
4.86B
Income
-172.29M
Revenue
568.41M
Book val./share
6.8
Cash/share
3.35
Dividend
-
Dividend %
-
Employees
1.24K
Optionable
No
Shortable
Yes
Earnings
31 Oct 2023
P/E
-28.01
Forward P/E
-
PEG
-1.55
P/S
8.54
P/B
6.08
P/C
12.24
P/FCF
-40.99
Quick Ratio
4.88
Current Ratio
5.94
Debt / Equity
0.13
LT Debt / Equity
0.11
-
-
EPS (TTM)
-1.49
EPS next Y
-
EPS next Q
-0.26
EPS this Y
175.47%
EPS next Y
-
EPS next 5Y
-28.19%
EPS last 5Y
1.43%
Revenue last 5Y
28.69%
Revenue Q/Q
9.33%
EPS Q/Q
20.45%
-
-
-
-
SMA20
-4.26%
SMA50
-21.05%
SMA100
-15.09%
Inst Own
76.77%
Inst Trans
1.14%
ROA
-17%
ROE
-22%
ROC
-0.2%
Gross Margin
74%
Oper. Margin
-31%
Profit Margin
-30%
Payout
-
Shs Outstand
117.42M
Shs Float
100.68M
-
-
-
-
Target Price
50
52W Range
23.81-63.57
52W High
-34.9%
52W Low
+78.3%
RSI
30
Rel Volume
0.76
Avg Volume
944.33K
Volume
717.33K
Perf Week
-17.53%
Perf Month
-18.18%
Perf Quarter
-24.07%
Perf Half Y
-18.36%
-
-
-
-
Beta
1.77162
-
-
Volatility
2.33%, 3.24%
Prev Close
-0.82%
Price
41.01
Change
-2.61%

TXG Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
1.776.292.954.444.54
Net income per share
-1.36-0.8-5.37-0.53-1.46
Operating cash flow per share
-0.920.89-2.15-0.19-0.3
Free cash flow per share
-1-0.21-2.53-1.11-1.45
Cash per share
0.7910.856.565.323.78
Book value per share
-2.6510.757.317.417.08
Tangible book value per share
-2.6510.757.097.146.84
Share holders equity per share
-2.6510.757.317.417.08
Interest debt per share
0.390.840.640.750.84
Market cap
4.37B2.98B14.32B16.44B4.15B
Enterprise value
4.34B2.59B13.72B15.93B4.02B
P/E ratio
-38.87-95.38-26.39-282.32-24.99
Price to sales ratio
29.8812.1247.9333.518.03
POCF ratio
-57.2386.08-65.73-769.07-123.46
PFCF ratio
-52.61-366.18-55.89-134.02-25.1
P/B Ratio
-19.887.119.3820.115.15
PTB ratio
-19.887.119.3820.115.15
EV to sales
29.6410.5245.9232.487.79
Enterprise value over EBITDA
-330.05-97.77-166.42-297.74-24.92
EV to operating cash flow
-56.7674.69-62.98-745.42-119.75
EV to free cash flow
-52.18-317.72-53.54-129.9-24.35
Earnings yield
-0.03-0.01-0.040-0.04
Free cash flow yield
-0.020-0.02-0.01-0.04
Debt to equity
-0.130.070.090.10.12
Debt to assets
0.240.050.070.080.09
Net debt to EBITDA
2.6914.917.289.450.77
Current ratio
3.287.636.566.774.85
Interest coverage
-45.98-9.44-50.73-61.1-352.82
Income quality
0.68-1.110.40.370.2
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.320.340.410.430.51
Intangibles to total assets
000.020.030.03
Capex to operating cash flow
0.09-1.240.184.743.92
Capex to revenue
-0.05-0.17-0.13-0.21-0.25
Capex to depreciation
-1.72-6.05-2.02-3.58-3.99
Stock based compensation to revenue
0.020.050.160.20.26
Graham number
913.929.79.3815.24
ROIC
0.58-0.07-0.1-0.06-0.17
Return on tangible assets
-0.9-0.05-0.6-0.06-0.17
Graham Net
-3.056.935.214.352.86
Working capital
73.87M417.79M656.24M637.23M504.08M
Tangible asset value
-219.99M420.08M716.72M787.66M778.37M
Net current asset value
-238.06M295M584.1M546.33M411.8M
Invested capital
-0.130.070.090.10.12
Average receivables
21.45M31.47M42.29M68.23M94.73M
Average payables
7.12M10.91M8.87M11.03M19.48M
Average inventory
6.7M11.92M22.61M44.96M70.8M
Days sales outstanding
73.7649.5462.5463.4473.66
Days payables outstanding
111.9777.9129.485.4865.49
Days of inventory on hand
109.1491.32187.03295.41247.49
Receivables turnover
4.957.375.845.754.96
Payables turnover
3.264.6812.424.275.57
Inventory turnover
3.3441.951.241.47
ROE
0.51-0.07-0.73-0.07-0.21
Capex per share
-0.08-1.09-0.38-0.92-1.16

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
1.011.151.361.161.26
Net income per share
-0.57-0.37-0.15-0.44-0.53
Operating cash flow per share
-0.15-0.080.12-0.04-0.1
Free cash flow per share
-0.39-0.4-0.23-0.08-0.32
Cash per share
4.43.963.753.623.35
Book value per share
6.96.87.026.946.8
Tangible book value per share
6.656.556.786.76.57
Share holders equity per share
6.96.87.026.946.8
Interest debt per share
0.870.840.830.880.85
Market cap
5.14B3.25B4.18B6.45B6.52B
Enterprise value
4.96B3.11B4.06B6.22B6.29B
P/E ratio
-19.93-19.38-60.73-31.78-26.1
Price to sales ratio
44.8424.7926.7748.0444.39
POCF ratio
-302.97-339.81304.73-1.56K-565.41
PFCF ratio
-116.32-70.44-160.77-685.71-176.7
P/B Ratio
6.564.195.198.048.21
PTB ratio
6.564.195.198.048.21
EV to sales
43.3123.7425.9746.3242.85
Enterprise value over EBITDA
-77.9-77.96-249.12-125.32-103.53
EV to operating cash flow
-292.64-325.41295.65-1.51K-545.78
EV to free cash flow
-112.36-67.46-155.98-661.23-170.56
Earnings yield
-0.01-0.010-0.01-0.01
Free cash flow yield
-0.01-0.01-0.010-0.01
Debt to equity
0.130.120.120.130.13
Debt to assets
0.10.10.090.10.1
Net debt to EBITDA
2.753.457.654.643.72
Current ratio
5.654.964.855.375.94
Interest coverage
-579.06-350.84-184.77-2.74K-12.67K
Income quality
0.260.23-0.80.080.18
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.620.510.410.50.49
Intangibles to total assets
0.030.030.030.030.03
Capex to operating cash flow
1.63.82-2.91.282.2
Capex to revenue
-0.24-0.28-0.25-0.04-0.17
Capex to depreciation
-3.22-4.51-4.69-0.61-2.13
Stock based compensation to revenue
0.320.260.260.310.31
Graham number
9.397.54.878.289.04
ROIC
-0.06-0.04-0.02-0.05-0.07
Return on tangible assets
-0.07-0.04-0.02-0.05-0.06
Graham Net
3.292.932.842.652.59
Working capital
548.32M502.57M504.08M489.89M484.85M
Tangible asset value
754.88M747.79M778.37M774.93M766.5M
Net current asset value
448.16M409.01M411.8M390.25M386.6M
Invested capital
0.130.120.120.130.13
Average receivables
76.37M79.88M93.88M91.08M82.81M
Average payables
22.84M24.16M21.6M25.46M26.22M
Average inventory
67.17M74.64M80.13M81.97M83M
Days sales outstanding
59.8457.3760.0352.2453.75
Days payables outstanding
86.8463.9852.7873.5144.09
Days of inventory on hand
229.5232.96199.49206.37159.55
Receivables turnover
1.51.571.51.721.67
Payables turnover
1.041.411.711.222.04
Inventory turnover
0.390.390.450.440.56
ROE
-0.08-0.05-0.02-0.06-0.08
Capex per share
-0.24-0.32-0.35-0.05-0.22

TXG Frequently Asked Questions

What is 10x Genomics, Inc. stock symbol ?

10x Genomics, Inc. is a US stock , located in Pleasanton of Ca and trading under the symbol TXG

Is 10x Genomics, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $50. The lowest prediction is $50 and the highest is $50

What is TXG stock prediction ?

What is 10x Genomics, Inc. stock quote today ?

10x Genomics, Inc. stock price is $41.01 today.

Is 10x Genomics, Inc. stock public?

Yes, 10x Genomics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap